ZyVet launches first generic treatment for canine urinary incontinence

ZyVet Animal Health, a leader in affordable generic pharmaceuticals for animals, a wholly owned subsidiary of Zydus Pharmaceuticals (USA), has released the first FDA-approved generic of phenylpropanolamine hydrochloride tablets, a trusted treatment for managing urinary incontinence in dogs.

This latest product underscores ZyVet's mission to bring trusted, high-quality, and cost-effective therapies to veterinary professionals across the United States.

Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus. Often seen in spayed females and aging dogs, urethral sphincter hypotonus can lead to frustrating and embarrassing accidents. ZyVet's generic provides dependable symptom relief while supporting stronger long-term client compliance. Available in multiple strengths to support precise dosing, the product is designed with the needs of both veterinary teams and pet owners in mind.

Speaking on this development, Punit Patel, President and CEO, Zydus Americas, said "Urinary incontinence affects quality of life for both pets and their families. Our phenylpropanolamine hydrochloride tablets deliver on both clinical reliability and affordability, enabling veterinarians to confidently treat more patients and maintain client compliance. We're proud to offer an option that removes cost as a barrier to compassionate care. With each launch, we reinforce that innovation doesn't need to come with a premium price tag - and that every pet should have access to high-quality treatment options."

ZyVet's rapid portfolio expansion leads a paradigm shift in the industry reinforcing that generic animal health products are as effective as the pioneer brands. As a division of Zydus Lifesciences, ZyVet benefits from more than 70 years of pharmaceutical, R&D, Regulatory, QA/QC, manufacturing scale, excellence and expertise.

Today, fewer than 20% of FDA-approved animal drugs have a generic version, highlighting the continued need for affordable veterinary therapies. With the launch of phenylpropanolamine hydrochloride tablets, ZyVet reinforces its role as a leader in the underserved generics space - bringing affordable innovation to animal care and making essential treatments more accessible for everyday pet owners and their veterinarians.